Jefferies Financial Group Boosts Eli Lilly and Company (NYSE:LLY) Price Target to $1,015.00

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by Jefferies Financial Group from $994.00 to $1,015.00 in a report issued on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reissued an overweight rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday. Argus upped their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a buy rating in a research note on Tuesday, May 14th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an outperform rating in a research report on Wednesday, May 1st. Bank of America reissued a buy rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a research note on Monday. Finally, TheStreet upgraded Eli Lilly and Company from a c+ rating to a b rating in a report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $812.72.

Eli Lilly and Company Stock Up 0.9 %

Shares of NYSE LLY opened at $909.04 on Monday. The company has a 50 day simple moving average of $807.55 and a 200 day simple moving average of $735.35. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $909.57. The firm has a market cap of $863.96 billion, a PE ratio of 133.33, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.62 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 9,671 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the sale, the insider now owns 97,574,139 shares in the company, valued at $88,077,248,051.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 9,671 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57. Following the completion of the transaction, the insider now directly owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock worth $672,385,964 over the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Lipe & Dalton purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $26,000. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $29,000. Core Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth $37,000. Finally, St. Johns Investment Management Company LLC boosted its position in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.